Chamath Palihapitiya

It's just that the truth sucks when you actually take it and you eat it.

It's just that the truth sucks when you actually take it and you eat it.

And you're like, it's in your tummy.

And you're like, it's in your tummy.

And you're like, No, this is not good.

And you're like, No, this is not good.

I don't like this.

I don't like this.

And so there's the censorship risk on the one hand, and then there's just the governance business risk for enterprises on the other.

And so there's the censorship risk on the one hand, and then there's just the governance business risk for enterprises on the other.

Both are not good.

Both are not good.

I think there's that, and I think that there's the risk of something that's more subtle, but equally insidious, which is that they will start to pick which corporations they want to benefit.

I think there's that, and I think that there's the risk of something that's more subtle, but equally insidious, which is that they will start to pick which corporations they want to benefit.

So for example, if Novartis has a competitive GLP-1 drug to Lilly, and they have a strategic deal with Novartis and not one with Lilly, now there's an impetus to shape how people get information.

So for example, if Novartis has a competitive GLP-1 drug to Lilly, and they have a strategic deal with Novartis and not one with Lilly, now there's an impetus to shape how people get information.

If they have a deal with JP Morgan, but not with Citibank, you'll just never know.

If they have a deal with JP Morgan, but not with Citibank, you'll just never know.

And so you'll ask a question, something about mortgage rates or interest rates, and you'll get all kinds of stuff that you don't understand.

And so you'll ask a question, something about mortgage rates or interest rates, and you'll get all kinds of stuff that you don't understand.